AlwatariYScheeseDGardnerG, et al. Surveillance Endoscopy After Foregut Surgery: Is It Necessary? Foregut. 2023;3(1):89-102. doi: 10.1177/26345161231160180
2.
ShaheenNJFalkGWIyerPG, et al. Diagnosis and management of Barrett’s esophagus: an updated ACG guideline. Am J Gastroenterol. 2022;117(4):559-587. doi:10.14309/ajg.0000000000001680
3.
EluriSReddySKetchemCC, et al. Low prevalence of endoscopic screening for Barrett’s esophagus in a screening-eligible primary care population. Am J Gastroenterol. 2022;117(11):1764-1771. doi:10.14309/ajg.0000000000001935
4.
Hvid-JensenFPedersenLDrewesAMSørensenHTFunch-JensenP. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375-1383. doi:10.1056/NEJMoa1103042.
5.
RoumansCAMvan der BogtRDSteyerbergEW, et al. Adherence to recommendations of Barrett’s esophagus surveillance guidelines: a systematic review and meta-analysis. Endoscopy. 2020;52:17-28. doi:10.1055/a-0995-0134
6.
VennalagantiPKanakadandiVGoldblumJR, et al. Discordance among pathologists in the United States and Europe in diagnosis of low-grade dysplasia for patients with Barrett’s esophagus. Gastroenterology. 2017;152(3):564-570.e4. doi:10.1053/j.gastro.2016.10.041
7.
SchnellTGSontagSJChejfecG, et al. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120(7):1607-1619.
8.
OldOMoayyediPLoveS, et al. Barrett’s oesophagus surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. J Med Screen. 2015;22(3):158-164. doi:10.1177/0969141315575052
9.
FitzgeraldRCSaeedITKhooDFarthingMJBurnhamWR. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett’s esophagus. Dig Dis Sci. 2001;46(9):1892-1898. http://www.ncbi.nlm.nih.gov/pubmed/11575441
10.
CorleyDAMehtaniKQuesenberryCZhaoWde BoerJWeissNS. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145(2):312-9.e1. doi:10.1053/j.gastro.2013.05.004
11.
RubensteinJHSonnenbergADavisJMcMahonLInadomiJM. Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc. 2008;68(5):849-855. doi:10.1016/j.gie.2008.02.062
12.
KearneyDJCrumpCMaynardCBoykoEJ. A case-control study of endoscopy and mortality from adenocarcinoma of the esophagus or gastric cardia in persons with GERD. Gastrointest Endosc. 2003;57(7):823-829. doi:10.1016/s0016-5107(03)70015-7
13.
CodipillyDCChandarAKSinghS, et al. The effect of endoscopic surveillance in patients with Barrett’s esophagus: a systematic review and meta-analysis. Gastroenterology. 2018;154(8):2068-2086.e5. doi:10.1053/j.gastro.2018.02.022
14.
CrockettSDLipkusIMBrightSD, et al. Overutilization of endoscopic surveillance in nondysplastic Barrett’s esophagus: a multicenter study. Gastrointest Endosc. 2012;75(1):23-31.e2. doi:10.1016/j.gie.2011.08.042
15.
BhatSColemanHGYousefF, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103(13):1049-1057. doi:10.1093/jnci/djr203
16.
ShaheenNJCrosbyMABozymskiEMSandlerRS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus?Gastroenterology. 2000;119(2):333-338.
17.
LagergrenJBergströmRLindgrenANyrénO. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825-831. doi:10.1056/NEJM199903183401101
18.
KroepSLansdorp-VogelaarIRubensteinJH, et al. An accurate cancer incidence in Barrett’s esophagus: A best estimate using published data and modeling. Gastroenterology. 2015;149(3):577-585.e4. doi:10.1053/j.gastro.2015.04.045. quiz e14-5.
19.
CottonCCShaheenNJThriftAP. Surveillance after treatment of Barrett’s esophagus benefits those with high-grade dysplasia or intramucosal cancer most. Am J Gastroenterol. 2022;117(7):1056-1062. doi:10.14309/ajg.0000000000001784
20.
GersonLBShetlerKTriadafilopoulosG. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology. 2002;123(2):461-467.
21.
DuitsLCPhoaKNCurversWL, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64(5):700-706. doi:10.1136/gutjnl-2014-307278
22.
CurversWLten KateFJKrishnadathKK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523-1530. doi:10.1038/ajg.2010.171
23.
WaniSFalkGWPostJ, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141(4):1179-1186.e1. doi:10.1053/j.gastro.2011.06.055
24.
van der WelMJDuitsLCPouwRE, et al. Improved diagnostic stratification of digitised Barrett’s oesophagus biopsies by p53 immunohistochemical staining. Histopathology. 2018;72(6):1015-1023. doi:10.1111/his.13462
25.
AbrahamJMMeltzerSJ. Long noncoding RNAs in the pathogenesis of Barrett’s esophagus and esophageal carcinoma. Gastroenterology. 2017;153(1):27-34. doi:10.1053/j.gastro.2017.04.046
26.
JammulaSKatz-SummercornACLiX, et al. Identification of subtypes of Barrett’s esophagus and esophageal adenocarcinoma based on DNA methylation profiles and integration of transcriptome and genome data. Gastroenterology. 2020;158(6):1682-1697.e1. doi:10.1053/j.gastro.2020.01.044
27.
van MunsterSLeclercqPHaidryR, et al. Wide area transepithelial sampling with computer assisted analysis (WATS3D) to detect high grade dysplasia and cancer in Barrett’s esophagus: a multi-center, randomized study. Endoscopy. Published online December13, 2022. doi:10.1055/a-1949-9542
28.
CurtiusKWongCJHazeltonWD, et al. A molecular clock infers heterogeneous tissue age among patients with Barrett’s esophagus. PLoS Comput Biol. 2016;12(5):e1004919. doi:10.1371/journal.pcbi.1004919
29.
Critchley-ThorneRJDavisonJMPrichardJW, et al. A tissue systems pathology test detects abnormalities associated with prevalent high-grade dysplasia and esophageal cancer in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2017;26(2):240-248. doi:10.1158/1055-9965.EPI-16-0640
30.
Critchley-ThorneRJDuitsLCPrichardJW, et al. A tissue systems pathology assay for high-risk Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2016;25(6):958-968. doi:10.1158/1055-9965.EPI-15-1164
31.
DavisonJMGoldblumJGrewalUS, et al. Independent blinded validation of a tissue systems pathology test to predict progression in patients with Barrett’s esophagus. Am J Gastroenterol. 2020;115(6):843-852. doi:10.14309/ajg.0000000000000556
32.
FreiNFKhoshiwalAMKonteK, et al. Tissue systems pathology test objectively risk stratifies Barrett’s esophagus patients with Low-Grade dysplasia. Am J Gastroenterol. 2021;116(4):675-682. doi:10.14309/ajg.0000000000001037
33.
FreiNFKonteKBossartEA, et al. Independent validation of a tissue systems pathology assay to predict future progression in nondysplastic Barrett’s esophagus: A spatial-temporal analysis. Clin Transl Gastroenterol. 2020;11(10):e00244. doi:10.14309/ctg.0000000000000244
34.
IyerPGCodipillyDCChandarAK, et al. Prediction of progression in Barrett’s esophagus using a tissue systems pathology test: A pooled analysis of international multicenter studies. Clin Gastroenterol Hepatol. 2022;20(12):2772-2779.e8 doi:10.1016/j.cgh.2022.02.033
35.
Bird-LiebermanELDunnJMColemanHG, et al. Population-based study reveals new risk-stratification biomarker panel for Barrett’s esophagus. Gastroenterology. 2012;143(4):927-35.e3. doi:10.1053/j.gastro.2012.06.041
36.
KadriSRLao-SirieixPO’DonovanM, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ. 2010;341:c4372. doi:10.1136/bmj.c4372
